Search research articles
Contact Us
Filters
Showing results (271-280 of 281) with videos related to
Page
of 29
Sort By:
Journal of Hepatology
|
September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Jordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 13, 2017
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
Cumali Efe, Hannes Hagström, Henriette Ytting, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Journal of Gastroenterology and Hepatology
|
August 14, 2020
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
Cumali Efe, Murat Torgutalp, Ida Henriksson, et al.
Annals of Hepatology
|
April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Donald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Gastroenterology
|
April 2, 2019
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis
Carolina Boni, Harry L A Janssen, Marzia Rossi, et al.
The American Journal of Gastroenterology
|
June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis
Cumali Efe, Koray Taşçilar, Ida Henriksson, et al.
Hepatology (Baltimore, Md.)
|
May 14, 2022
Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome
Cumali Efe, Anand V Kulkarni, Benedetta Terziroli Beretta-Piccoli, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 281) with videos related to
Sort By:
Page
of 29
Journal of Hepatology
|
September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Jordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 13, 2017
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
Cumali Efe, Hannes Hagström, Henriette Ytting, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Journal of Gastroenterology and Hepatology
|
August 14, 2020
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
Cumali Efe, Murat Torgutalp, Ida Henriksson, et al.
Annals of Hepatology
|
April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Donald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Gastroenterology
|
April 2, 2019
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis
Carolina Boni, Harry L A Janssen, Marzia Rossi, et al.
The American Journal of Gastroenterology
|
June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis
Cumali Efe, Koray Taşçilar, Ida Henriksson, et al.
Hepatology (Baltimore, Md.)
|
May 14, 2022
Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome
Cumali Efe, Anand V Kulkarni, Benedetta Terziroli Beretta-Piccoli, et al.
Page
of 29